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Adult skeletal muscle has resident stem cells, 
called satellite cells, which are responsible for 
generating new muscle under both physiologi-
cal and pathophysiologic conditions. Although 
these muscles have the capacity to regenerate, 
this capacity has some limitations (Le Grand 
and Rudnicki, 2007). There are several skeletal 
muscle diseases such as skeletal muscle dys-
trophy,  myopathy,  severe  injury,  and  disuse 
syndrome  for  which  there  are  no  effective 
treatments (Shi and Garry, 2006). Although sev-
eral studies have identified various growth fac-
tors and cytokines that regulate skeletal muscle 
development and regeneration, effective con-
trol of regeneration hasn’t been achieved using 
these factors in the clinical setting (Buckingham 
and  Montarras,  2008). Therefore,  it  is  worth 
elucidating the mechanisms of skeletal muscle 
regeneration  and  developing  novel  regenera-
tion therapies.
After injury to skeletal muscle, neutrophils, 
monocytes,  and  macrophages  infiltrate  the 
damaged area. Concomitantly, satellite cells dif-
ferentiate into transient-amplifying myoblasts, 
which rapidly proliferate, fuse with one another, 
and regenerate skeletal myotubes. During these 
processes,  inflammation  and  regeneration  are 
tightly linked. Therefore, it is reasonable to as-
sume that some factors expressed during the 
inflammatory process influence skeletal muscle 
regeneration. However, the precise mechanisms 
remain unknown.
Previously, when we looked for potent dif-
ferentiation-promoting factors during embry-
onic stem cell differentiation (Yuasa et al., 2005, 
2010), we noted a marked elevation in the ex-
pression of G-CSF receptor (G-CSFR; encoded 
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After skeletal muscle injury, neutrophils, monocytes, and macrophages infiltrate the dam-
aged area; this is followed by rapid proliferation of myoblasts derived from muscle stem 
cells (also called satellite cells). Although it is known that inflammation triggers skeletal 
muscle regeneration, the underlying molecular mechanisms remain incompletely under-
stood. In this study, we show that granulocyte colony-stimulating factor (G-CSF) receptor 
(G-CSFR) is expressed in developing somites. G-CSFR and G-CSF were expressed in myo-
blasts of mouse embryos during the midgestational stage but not in mature myocytes. 
Furthermore, G-CSFR was specifically but transiently expressed in regenerating myocytes 
present in injured adult mouse skeletal muscle. Neutralization of endogenous G-CSF with a 
blocking antibody impaired the regeneration process, whereas exogenous G-CSF supported 
muscle regeneration by promoting the proliferation of regenerating myoblasts. Further-
more, muscle regeneration was markedly impaired in G-CSFR–knockout mice. These find-
ings indicate that G-CSF is crucial for skeletal myocyte development and regeneration and 
demonstrate the importance of inflammation-mediated induction of muscle regeneration.
© 2011 Hara et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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G-CSF and G-CSFR are expressed in differentiating  
skeletal myocytes
Immunostaining for markers of several differentiation stages 
revealed the stage at which skeletal myocytes expressed the 
G-CSFR. Skeletal muscle progenitor cells arise in the central 
part of the dermomyotome, coexpress Pax3 and Pax7, and can 
differentiate into skeletal muscle fibers during embryogenesis 
(Messina and Cossu, 2009). Pax3 and Pax7 have partially 
overlapping and partially distinct functions in myogenic pro-
genitor cells and are both down-regulated during myogenic 
differentiation, after myogenic regulatory factor (MRF) ex-
pression. The Pax3- and Pax7-expressing myogenic progeni-
tor cells didn’t express G-CSFR (Fig. 1 c). However, the cells 
with declining levels of Pax3 and Pax7, which started to ex-
press MyoD and myogenin, showed G-CSFR expression 
(Fig. 1 d). In agreement with a previous study on the G-CSFR 
expression pattern, the immunoreactivity for G-CSFR was 
localized to the cell membrane and cytoplasm under steady-
state conditions (Aarts et al., 2004). These cells also expressed 
desmin, which is an intermediate filament expressed in skele-
tal muscle (Fig. 1 d).
G-CSF expression was also examined by immunostaining. 
G-CSF expression wasn’t detected in the Pax3- and Pax7- 
expressing myogenic progenitor cells (Fig. 1 e). As seen for 
the G-CSFR–expressing cells, the cells with declining levels of 
Pax3 and Pax7, which started to express MyoD and myogenin, 
showed G-CSF expression (Fig. 1 f). Double immunostaining 
for G-CSF and G-CSFR revealed that the G-CSFR–expressing 
cells also expressed G-CSF. These results indicate that early 
skeletal  myocyte  differentiating  cells  undergo  autocrine   
G-CSF signaling in the developing myoblasts.
G-CSF promotes myoblast proliferation in vitro
To elucidate the role of G-CSF in myogenic cells, myoblast 
cells were analyzed in vitro. The C2C12 cell line is a subclone 
of C2 cells, which were established from the regenerating 
thigh muscle of an adult mouse and which are widely used as 
a myoblast cell line (Blau et al., 1983). In low-serum condi-
tions, C2C12 cells differentiate and fuse with each other to 
form multinucleated myotubes (Fig. 2 a). Immunostaining for 
G-CSFR and -actinin revealed that the premature C2C12 
cells expressed G-CSFR but not actinin, whereas the mature 
fused myotubes clearly expressed -actinin, and the -actinin–
positive cells never expressed G-CSFR. Western blot analysis 
confirmed  that  as  differentiation  proceeded,  -actinin  ex-
pression  gradually  increased,  and  G-CSFR  expression  de-
creased (Fig. 2 b).
To clarify the effect of G-CSF on myocytes, G-CSF was 
administered to C2C12 cells that expressed the G-CSFR. G-CSF 
administration significantly increased the number of C2C12 
cells in a dose-dependent manner (Fig. 2 c). BrdU incorpora-
tion analysis revealed that the increased cell number was the 
result of cell proliferation induced by G-CSF (Fig. 2 d). An anti–
G-CSF neutralizing antibody inhibited the serum-dependent 
proliferation of C2C12 cells (Fig. 2 e). We also examined 
whether G-CSF may affect the myogenic cell differentiation. 
by csf3r) in developing cardiomyocytes (Shimoji et al., 2010). 
Interestingly, we also found a marked increase in G-CSFR 
expression in developing somites. G-CSF was initially identi-
fied as a hematopoietic cytokine and has been used in both 
basic research studies and in the clinic for the mobilization of 
hematopoietic stem cells (Demetri and Griffin, 1991; Welte   
et al., 1996; Metcalf, 2008). However, recently, studies suggest 
that G-CSF also plays roles in cell differentiation, prolifera-
tion, and survival (Avalos, 1996; Harada et al., 2005; Zaruba   
et al., 2009). These findings encouraged us to investigate the 
involvement of G-CSF and G-CSFR in skeletal myocyte de-
velopment and regeneration and to examine the link between 
inflammation and regeneration.
In this study, we show that skeletal myoblasts express   
G-CSF/G-CSFR and proliferate in an autocrine fashion in skel-
etal myocyte development. We also show that both infiltrating 
inflammatory cell–derived G-CSF and externally administered 
G-CSF enhance skeletal myoblast proliferation and facilitate 
skeletal muscle regeneration.
RESULTS
csf3r is expressed in the developing somite
Initially, we investigated the csf3r expression in the developing 
mouse embryo. Whole-mount in situ hybridization revealed 
that csf3r was expressed in the somite of the embryonic day (E) 
9.5 mouse embryo. To localize csf3r expression within the 
somites, we used several markers of skeletal myocyte differen-
tiation (Fig. 1 a). The c-met gene, which encodes a receptor for 
hepatocyte growth factor, is expressed in the dermomyotome 
and is essential for the delamination/migration of muscle pro-
genitor cells (Yang et al., 1996). The expression of c-met was 
restricted to the ventral portion of the somite, and the expres-
sion pattern of csf3r wasn’t similar to that of c-met. Skeletal 
myocyte development is finely regulated by myogenic tran-
scription factors. pax3 is first expressed in the presomitic 
mesoderm and is expressed in the somitic epithelium of the 
dermomyotome (Jostes et al., 1990; Bober et al., 1994). pax3 
is repressed as dermomyotome-derived cells activate myogenic 
transcription factors. The expression pattern of pax3 was dif-
ferent from that of csf3r. The myogenic bHLH (basic helix-loop-
helix) genes also show unique expression patterns in different 
skeletal muscle developmental stages. myoD and myf5 are ex-
pressed in undifferentiated proliferating myoblasts (Tapscott 
et al., 1988; Venters et al., 1999), whereas mrf4 isn’t expressed 
until a late stage in the differentiation program (Rhodes and 
Konieczny,  1989;  Bober  et  al.,  1991).  Compared  with  these 
marker expression patterns, the csf3r expression pattern resem-
bled those of myf5 and myoD. The expression pattern of the late 
differentiation marker mrf4 wasn’t identical to that of csf3r.
Immunofluorescence staining of sections of embryos of 
different developing stages demonstrated that G-CSFR ex-
pression in the somite was restricted to the E9.5–10.5 period; 
before E9.5, G-CSFR wasn’t observed in the somite, and by 
E11.5, G-CSFR expression had disappeared (Fig. 1 b). These 
results indicate that G-CSF is involved in the development of 
undifferentiated proliferating myoblasts.JEM VOL. 208, April 11, 2011 
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Figure 1.  G-CSFR and G-CSF are expressed in developing somites after the midgestation stage. (a) Whole-mount in situ hybridization for  
c-met, pax3, myoD, csf3r, and mrf4 in E9.5 embryos. The -galactosidase staining for myf5 nLacZ knockin mice in E9.5 embryo is also shown. (b) Immuno-
staining for G-CSFR and nuclei (DAPI) in E8.5, E9.5, E10.5, and E11.5 mouse embryos. (c) Triple immunofluorescence staining for Pax3, Pax7, and G-CSFR in 
an E10.5 embryo. DAPI indicates nuclear stain. (d) Triple immunofluorescence staining for MyoD, myogenin, desmin, G-CSFR, and nuclei (DAPI) in an E10.5 
embryo. (e) Triple immunostaining for G-CSF, Pax3, Pax7, and nuclei (DAPI) in an E10.5 embryo. (f) Triple immunofluorescence staining for MyoD, myo-
genin, desmin, G-CSF, and nuclei (DAPI) in an E10.5 embryo. (g) Triple immunostaining for G-CSFR, G-CSF, and nuclei (DAPI) in an E10.5 embryo.  
(c, d, f, and g) Boxed areas are shown at higher magnification in the images to the right (c) or below (d, f, and g). Representative photographs in a are 
from three independent experiments with 10 embryos. Results in b–g are from five independent experiments.718 G-CSF promotes skeletal muscle regeneration | Hara et al.
Figure 2.  G-CSF increases myoblast proliferation. (a) Phase-contrast micrography (top) and immunofluorescence (bottom) imaging of G-CSFR and 
-actinin in C2C12 myoblast cell line before (day 1) and during (day 6) differentiation induced by low-serum conditions. Inset images are shown at 
higher magnification. (b) G-CSFR and -actinin expression was analyzed by Western blot in differentiating C2C12 cells. GAPDH was a loading control.  
(c) C2C12 cells were cultured with or without the indicated concentrations of G-CSF in low-serum conditions. Cells were counted at the indicated time 
points. (d) C2C12 cells were cultured with or without G-CSF in low-serum conditions and were pulsed with BrdU. BrdU incorporation was measured at 
day 3 of differentiation. (e) C2C12 cells were incubated without serum or with serum and the indicated concentrations of G-CSF neutralizing antibody. 
Cells were counted on day 5 of culture. (f) C2C12 cells were cultured with or without G-CSF for the indicated time points, and phosphorylated and total JEM VOL. 208, April 11, 2011 
Article
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expressed in the regenerating myocytes on day 5 after car-
diotoxin injection (Fig. 3 c). The G-CSFR–positive cells were 
larger than the infiltrated inflammatory cells, round-shaped 
with centrally located nuclei, and completely surrounded 
by laminin. Thus, these cells were identified as regenerating 
early myocytes that expressed G-CSFR. Serial immuno-
fluorescence staining analyses showed that the G-CSFR– 
expressing cells appeared only from day 3 to 8 after injury 
(Fig. 3, d and e).
Muscle repair is characterized by discrete stages of regen-
eration. In this time period, skeletal muscle regeneration in-
volves the activation of satellite cell or transient-amplifying 
cell  proliferation,  differentiation,  and  maturation  (Shi  and 
Garry, 2006). The G-CSFR–expressing day corresponds to 
the skeletal muscle progenitor cell proliferation day.
Exogenous G-CSF augments skeletal muscle regeneration
To determine whether external administration of G-CSF fa-
cilitates skeletal myocyte regeneration, G-CSF was injected 
after skeletal muscle injury. G-CSF was administered i.v. or 
was injected i.m. into the injured muscle on day 4 and 6, at 
which time point G-CSFR was strongly expressed, and skel-
etal muscle regeneration was observed on day 7. For higher 
G-CSF  dosages,  i.v.  administration  was  more  effective  for 
skeletal  muscle  regeneration  than  PBS  administration.  For 
lower G-CSF dosages, i.m. administration was more effective 
than i.v. (Fig. 4 a). The number of regenerating myocytes was 
significantly increased by G-CSF administration, and G-CSF 
administered i.m. significantly augmented skeletal muscle re-
generation (Fig. 4 b). G-CSF administration also significantly 
increased the diameter of the regenerated muscle. The diame-
ter of the rectus femoris was increased to a greater extent by 
G-CSF administered i.m. than i.v. (Fig. 4 c). Functional recovery 
was assessed by measuring handgrip strength after cardiotoxin 
injection into forearm muscles. G-CSF treatment significantly 
improved functional recovery on 5 and 7 d after skeletal mus-
cle injury (Fig. 4 d).
To investigate whether innate G-CSF signaling is neces-
sary for skeletal myocyte regeneration, an anti–G-CSF neu-
tralizing antibody was administered after injury. This antibody 
reduced spontaneous skeletal myocyte regeneration in a dose-
dependent manner (Fig. 4 e). The number of regenerating 
myocytes was drastically deceased by treatment with the anti–
G-CSF antibody (Fig. 4 f). The diameter of the injured muscle 
was also significantly decreased by treatment with the anti– 
G-CSF antibody (Fig. 4 g). Individual skeletal myocyte areas in 
G-CSF treatment and anti–G-CSF neutralizing antibody ad-
dition were measured at day 7 after injury. At day 7, there was 
a substantial amount of regenerating myocytes, which were 
small compared with uninjured myocytes. So, the mean of   
G-CSF was administered during C2C12 differentiation at 
different time points (Fig. S1 a), and myocyte differentiated 
marker expression was examined. Although G-CSF significantly 
increases the number of myocytes, G-CSF didn’t affect the 
myocyte differentiated marker expression (Fig. S1 b). Thus, 
G-CSF plays an essential role in C2C12 cell proliferation.
The binding of G-CSF to its receptor activates various 
signals, including extracellular regulated kinase (ERK), c-Jun 
N-terminal kinase (JNK), p38MAPK, AKT, and STAT, in 
hematopoietic cells (Avalos, 1996). We confirmed that G-CSF 
activated STAT3, AKT, ERK, JNK, and p38MAPK in C2C12 
cells in a time-dependent manner (Fig. 2 f). Of these factors, 
STAT3 has been reported to contribute to the proliferation of 
myocyte precursor cells (Megeney et al., 1996; Serrano et al., 
2008). G-CSF addition to C2C12 cell cultures increased the 
activity of acute phase response element (APRE) luciferase, 
which responds to STAT3 activation (Fig. 2 g). These results 
indicate that G-CSF promotes the proliferation of C2C12 
myoblasts through G-CSFR.
The G-CSFR is transiently expressed in regenerating  
skeletal myocytes
In general, the regeneration process resembles the mechanism 
of physiological development. Based on the finding that   
G-CSFR was transiently expressed in the developing somite, 
we expected that regenerating skeletal muscle would express 
G-CSFR and examined whether it was expressed in regener-
ating skeletal myocytes after injury. Cardiotoxin damages the 
myofiber plasma membrane but leaves the basal lamina, satel-
lite cells, and nerves intact, allowing rapid and reproducible 
muscle regeneration (Hosaka et al., 2002). We injected cardio-
toxin directly into the femoral muscles and performed a serial 
histological analysis up to day 28 after injury. After cardio-
toxin injection, spontaneous regeneration of the injured mus-
cle was observed (Fig. 3 a and Fig. S2). From day 1 to 2, 
several inflammatory cells infiltrated the injured muscle, and 
the injured myotubes were absorbed. The number of satellite 
cells or transient-amplifying cells began to increase from day 3, 
and regenerating myocytes that have centrally located nuclei 
were clearly identified from day 5 (Yan et al., 2003; Shi and 
Garry, 2006; Clever et al., 2010). These cells fused and rapidly 
increased in diameter thereafter. The injured area was filled 
with the regenerated myotubes, which had centrally located 
nuclei and smaller diameters than the matured myotubes from 
day 7. On day 28, the regenerated myotubes had almost the 
same diameter as the noninjured myotubes, although they had 
centered nuclei.
Triple immunostaining for laminin, G-CSFR, and DAPI re-
vealed the absence of G-CSFR–positive cells in the noninjured 
skeletal muscle (Fig. 3 b). In contrast, G-CSFR was clearly 
proteins were measured by Western blot. p, phospho. (g) C2C12 cells were transfected with a STAT3-responsive APRE luciferase reporter construct and 
were cultured with or without the indicated concentrations of G-CSF. Luciferase activity (relative to control) was measured on day 2 of culture.  
(c–e and g) Error bars present mean ± SD (*, P < 0.05). Micrographs in a are representative of five independent experiments. Results in b and f are from 
three independent experiments. Results in c–e and g are from five independent experiments.
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approximately half as many as that of wild-
type  (csf3r+/+)  mice.  Normally,  delivered 
csf3r/ mice showed no significant differ-
ences in appearance. When fully grown, the 
body size of the csf3r/ mouse was slightly 
but  significantly  smaller  than  that  of  the 
csf3r+/+ mouse. The initial histological analy-
sis of the skeletal muscle of the csf3r/ 
mouse  revealed  no  significant  difference 
compared with that of the csf3r+/+ mouse 
(Fig. 5 a). However, in the sections of skele-
tal muscles, the myocytes were slightly but 
significantly larger in the csf3r/ mice than 
in the csf3r+/+ mice (Fig. 5 b). Moreover, the 
diameter of the rectus femoris was signifi-
cantly smaller in the csf3r/ mouse than in 
the wild-type mouse (Fig. 5 c). Although 
skeletal myocyte proliferation is correlated 
with  hypertrophy  in  some  situations,  the 
molecular pathway of skeletal myocyte pro-
liferation is an independent event of skeletal 
muscle hypertrophy (Rantanen et al., 1995; 
Adams  et  al.,  1999; Armand  et  al.,  2005; 
Philippou et al., 2007). And more, skeletal 
muscle hypertrophy is an adaptation process for physiological 
requirements (Sakuma et al., 2000; Solomon and Bouloux, 
2006). These findings suggest that in the csf3r/ mouse, 
skeletal muscle proliferation is reduced during develop-
ment, and, as a consequence, the skeletal myocytes are adap-
tively hypertrophic.
To investigate whether innate G-CSFR is necessary for 
skeletal myocyte regeneration, csf3r/ mice were subjected 
to cardiotoxin-induced skeletal muscle injury. The csf3r/ 
mice showed deterioration of skeletal muscle regeneration on 
day 7 and 14 after injury in the rectus femoris muscles (Fig. 5 d). 
The number of regenerating myocytes in the regenerating 
skeletal  muscle  was  significantly  decreased  in  the  csf3r/ 
mice (Fig. 5 e), which suggests the G-CSFR is essential for 
skeletal muscle regeneration. To confirm that the observed effect 
of G-CSF occurred through the G-CSFR, we administrated 
individual skeletal myocyte areas is inversely correlated with 
regeneration in G-CSF treatment and anti–G-CSF neutraliz-
ing antibody administration (Fig. 4 h). However, at day 14, re-
generated myocytes grew up to uninjured muscle, and there 
were no significant differences among those groups (unpub-
lished  data). These  results  indicate  that  exogenous  G-CSF 
augments skeletal myocyte regeneration and that physiologi-
cal G-CSF signaling plays an essential role in innate skeletal 
myocyte regeneration.
The csf3r/ mouse shows impaired skeletal muscle 
development and regeneration
To clarify the roles of G-CSF and G-CSFR signaling in skel-
etal  myocytes,  G-CSFR–knockout  (csf3r/)  mice  were 
used. To date, csf3r/ mice have been used mainly in he-
matologic studies. The number of delivered csf3r/ mice was 
Figure 3.  The G-CSFR is expressed in adult  
regenerating skeletal myocytes. (a) Histological  
analysis of cardiotoxin-injured skeletal muscle.  
Hematoxylin and eosin staining of the rectus femoris.  
(b and c) Triple immunostaining of noninjured (b; day 0) 
and injured (c; day 5) skeletal muscles for the de-
tection of G-CSFR, laminin, and nuclei (DAPI). (d) Time 
course of G-CSFR expression in regenerating skeletal 
myocytes. Immunofluorescently stained injured skel-
etal muscles on days 1, 5, 8, and 14 are shown.  
(e) Percentages of G-CSFR–positive cells. The percent-
ages of G-CSFR–positive regenerating skeletal muscle 
cells were assessed on days 1–9 after injury. Error bars 
present mean ± SD. Representative photomicrographs 
in a are from three independent experiments. Results 
in b–e are from five independent experiments.JEM VOL. 208, April 11, 2011 
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Figure 4.  Both intrinsic and extrinsic G-CSF augment skeletal muscle regeneration. (a) Effect of i.v. or i.m. administration of G-CSF on cardiotoxin- 
induced skeletal muscle injury. Hematoxylin and eosin staining of injured rectus femoris 7 d after cardiotoxin injection. (b) Numbers of regenerating myocytes that 
have centrally located nuclei. 20 visual fields per individual mice were observed in the rectus femoris at 7 d after cardiotoxin injection. (c) Diameter of the regener-
ated rectus femoris at 7 d after cardiotoxin injection. (d) Handgrip strength on day 3–7 after cardiotoxin injury. (e) Role of the intrinsic G-CSF signal in skeletal 
muscle regeneration. Hematoxylin and eosin staining of an injured rectus femoris on day 7 is shown. (f) Numbers of regenerating myocytes that have centrally 
located nuclei. 20 visual fields per individual mice were observed in the rectus femoris at 7 d after cardiotoxin injection. (g) The diameter of the injured rectus 
femoris is shown with or without the anti–G-CSF neutralizing antibody (Ab) at 7 d after cardiotoxin injection. (h) Quantitative analysis of the areas of the skeletal 
myocyte sections. CTX, cardiotoxin. (b–d and f–h) Error bars present mean ± SD (*, P < 0.05). Results in a–h are from eight independent experiments.722 G-CSF promotes skeletal muscle regeneration | Hara et al.
the regenerating skeletal muscles were measured. G-CSF ad-
ministration significantly increased the numbers of regenerat-
ing myocytes in the csf3r+/+ mice but not in the csf3r/ mice 
(Fig. 5 g). Functional recovery was assessed by measuring hand-
grip strength after cardiotoxin injection into forearm muscles. 
G-CSF to the csf3r/ mice. If G-CSF functions through 
other receptors, the addition of G-CSF should still improve 
the skeletal muscle regeneration of csf3r/ mice. Exogenous 
G-CSF administration didn’t improve skeletal muscle regen-
eration (Fig. 5 f). The numbers of regenerating myocytes in 
Figure 5.  The csf3r/ mouse shows impaired skeletal muscle development and regeneration. (a) Hematoxylin and eosin staining of the rectus 
femoris of a wild-type mouse and a csf3r/ mouse. (b) Quantitative analysis of the areas of the skeletal myocyte sections in the wild-type and csf3r/ 
mice. (c) The diameter of the rectus femoris is shown. (d) Hematoxylin and eosin staining of the cardiotoxin-injured skeletal muscles of the wild-type and 
csf3r/ mice at 7 and 14 d after injury. (e) Numbers of regenerating myocytes that have centrally located nuclei on days 7 and 14 after injury in the 
regenerating skeletal muscles of the wild-type and csf3r/ mice. 20 visual fields per individual mice were observed in the rectus femoris. (f) Effects of 
extrinsic G-CSF administration on cardiotoxin-induced muscle injury in the wild-type and csf3r/ mice. Hematoxylin and eosin staining of injured skel-
etal muscle on day 7 after cardiotoxin injection is shown. (g) Effect of extrinsic G-CSF administration on cardiotoxin-induced skeletal myocyte injury, as 
assessed by the numbers of regenerating myocytes. 20 visual fields per individual mice were observed in the rectus femoris at 14 d after cardiotoxin  
injection. (b, c, e, and g) Error bars present mean ± SD (*, P < 0.05). (h) Handgrip strengths of cardiotoxin-injected csf3r/ mice with or without G-CSF 
treatment. Results in a–h are from eight independent experiments.JEM VOL. 208, April 11, 2011 
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muscle regeneration, which suggests that G-CSF is critical for 
skeletal muscle regeneration.
During  development,  early  muscle  progenitor  cells  are 
characterized by Pax3 and Pax7 expression. Pax3 and Pax7 
cooperatively specify the muscle progenitor pool because in 
mice deficient for both Pax3 and Pax7, all muscle progenitor 
cells are absent (Kassar-Duchossoy et al., 2005; Relaix et al., 
2005). Once specified, muscle progenitor cells either prolifer-
ate or exit the cell cycle to undergo terminal differentiation. 
The latter process requires the activation of MRFs (Sabourin 
and Rudnicki, 2000). G-CSFR was expressed in cells that 
expressed MRFs but not in early muscle progenitor cells. 
Therefore, we speculate that rather than inducing early progeni-
tor cells to increase the skeletal muscle stem cell pool, G-CSF 
causes late progenitor cells to adopt muscle mass requirement. 
In adult skeletal muscle, myogenic progenitor cells, which are 
characterized by the expression of MyoD, Myf5, or MRF4, 
and myoblasts, which are characterized by MyoD and Myf5 
expression, are known as transient-amplifying cells (Weintraub, 
1993; Shi and Garry, 2006; Kuang and Rudnicki, 2008;   
Biressi and Rando, 2010). We found that in the adult stage, 
G-CSFR was expressed in myoblasts, and G-CSF increased 
myocyte proliferation.
G-CSF is a hematopoietic cytokine that recruits hemato-
poietic cells (Cottler-Fox et al., 2003). The contribution of 
BM cells to muscle regeneration has been documented (Ferrari 
et al., 1998; Gussoni et al., 1999; LaBarge and Blau, 2002).   
To exclude the possibility that hematopoietic cells and BM 
mesenchymal stem cells affect skeletal muscle regeneration in 
response to G-CSF, we transferred wild-type BM cells to 
csf3r/ mice. In these mice, the skeletal myocytes didn’t ex-
press G-CSFR, whereas the BM cells expressed G-CSFR. If 
BM cells contributed to skeletal muscle regeneration, these 
mice would show normal or improved regeneration abilities. 
However, they didn’t show skeletal muscle regeneration in 
response to G-CSF. This finding is consistent with a report 
that stromal progenitor cells are mobilized by vascular endo-
thelial growth factor but not by G-CSF (Pitchford et al., 
2009). We assume that the contribution of BM cells to   
G-CSF–mediated skeletal muscle regeneration is negligible.
Skeletal muscle regeneration is a complex process that re-
mains to be fully understood. After muscle injury, disruption 
of the myofiber plasma membrane initiates an influx of extra-
cellular  calcium,  leading  to  calcium-dependent  proteolysis, 
which results in necrosis and degeneration of the myofibers. 
Several  signals  released  from  the  degenerating  myocytes   
attract and activate inflammatory cells, which secrete cytokines. 
Neutrophils are the first inflammatory cells to reach the in-
jured myofibers, followed by macrophages, which phagocyte 
the degenerating muscle fibers (Chargé and Rudnicki, 2004). 
Satellite cells and macrophages interact to amplify chemotaxis 
and enhance inflammation. Monocytes and macrophages may 
support satellite cell survival by cell–cell contacts and the re-
lease of soluble factors (Chazaud et al., 2003). In addition, mono-
cyte and macrophage infiltration leads to increased satellite 
cell proliferation and differentiation (Lescaudron et al., 1999). 
G-CSF administration didn’t confer functional recovery on 
day 5 or 7 after injury (Fig. 5 h). To elucidate precise myo-
blast function, we also examined the proliferation ability of 
csf3r/ myoblasts in vitro. The csf3r/ myoblasts showed sig-
nificant decreased proliferation ability (Fig. S1 c). However, the 
expression of myocyte differentiation marker was not altered, 
which indicates that myocyte differentiation ability was not im-
paired in csf3r/ myoblasts (Fig. S1 d).
G-CSFR–expressing BM cells do not recover skeletal muscle 
regeneration in the csf3r/ mouse
To clarify the involvement of hematopoietic cells or BM cells 
in the impairment of skeletal muscle regeneration, we trans-
planted the BM cells from csf3r+/+ mice, which constitutively 
expressed GFP, to the csf3r/ mice (Fig. 6 a) 60 d before 
cardiotoxin-induced injury. In all the mice, the BM cells sta-
bly engrafted, and chimerism was >80%, as assessed by FACS 
(Fig. S3 a). After cardiotoxin injection into forearm muscles, 
the csf3r/ mice that were transplanted with BM cells from 
csf3r+/+ mice didn’t show any improvement in gross morphol-
ogy, the number of central cells, and handgrip strength after 
G-CSF treatment (Fig. 6, b–d). Moreover, the diameter of 
rectus femoris in these mice wasn’t improved by G-CSF treat-
ment after cardiotoxin injection into the rectus femoris mus-
cles (Fig. 6 e). These mice showed no significant improvement 
in the regeneration by G-CSF treatment, and myocyte area 
was not altered by G-CSF treatment either (Fig. S3 b).
Next, we performed the BM transplantation experiment 
in reverse; the BM cells from csf3r/ mice were transplanted 
into csf3r+/+ mice. In these mice, skeletal muscle injury was 
generated, and regeneration was induced with G-CSF (Fig. 6 f). 
G-CSF treatment markedly improved gross morphology, the 
number of central cells, and handgrip strength after cardio-
toxin injection into forearm muscles (Fig. 6, g–i) and in-
creased the diameter of the rectus femoris after cardiotoxin 
injection into the rectus femoris muscles (Fig. 6 j). These 
mice showed more regeneration, and mean myocyte area was 
decreased by G-CSF treatment (Fig. S3 c). These results in-
dicate that G-CSF promotion of skeletal muscle regenera-
tion is a direct effect on skeletal muscle and isn’t mediated by 
BM cells.
DISCUSSION
This study demonstrates that G-CSF and G-CSFR play piv-
otal roles in skeletal myocyte development and regeneration. 
Interestingly, this mechanism about G-CSF and G-CSFR is 
conserved between embryonic skeletal myocyte development 
and adult skeletal myocyte regeneration. G-CSFR is tran-
siently but strongly expressed in myoblasts during develop-
ment. The total mass of skeletal muscle is lower in csf3r/ 
mice than in csf3r+/+ mice, which means that G-CSF and   
G-CSFR signaling are essential for proper skeletal muscle   
development. G-CSFR is also expressed in the regenerating 
adult myocyte. G-CSF stimulates these G-CSFR–expressing 
myoblasts and promotes skeletal muscle regeneration after in-
jury. The csf3r/ mice showed drastic impairment of skeletal 724 G-CSF promotes skeletal muscle regeneration | Hara et al.
Based on our results, we speculate that macrophages are 
not only important for the resolution of necrosis but also in-
volved in the induction of muscle regeneration. These leuko-
cytes secrete G-CSF in the presence of appropriate stimuli 
(Hareng  and  Hartung,  2002).  Although  previous  studies 
showed that G-CSF seems to have some positive effects on 
skeletal muscle regeneration, it’s not clear how G-CSF affects 
skeletal muscle regeneration, and especially the involvement 
Figure 6.  Effect of transplanted G-CSFR–expressing BM cells on skeletal muscle regeneration. (a) Experimental model of BM transplantation 1.  
BM cells were isolated from GFP-transgenic (Tg) mice and transplanted into the csf3r/ mice. Cardiotoxin was injected into the rectus femoris, and G-CSF was 
administered on days 4 and 6. (b–e) Effects of G-CSF on skeletal muscle regeneration of csf3r/ mice subjected to cardiotoxin-induced skeletal myocyte 
injury and transplanted with wild-type BM (from GFP-transgenic mice). (b) Hematoxylin and eosin staining of the cardiotoxin-injured skeletal muscles at 7 d 
after injury. (c) Effect of extrinsic G-CSF administration on cardiotoxin-induced skeletal myocyte injury, as assessed by the numbers of regenerating myocytes. 
20 visual fields per individual mice were observed in the rectus femoris at 14 d after cardiotoxin injection. (d and e) Effects of G-CSF on the handgrip strength 
(d) and rectus femoris diameter at 14 d (e) are negligible. (f) Experimental model of BM transplantation 2. BM cells were isolated from csf3r/ mice and 
transplanted into the wild-type (csf3r+/+) mice. (g) Hematoxylin and eosin staining of the cardiotoxin-injured skeletal muscles at 7 d after injury. (h) Effect of 
extrinsic G-CSF administration on cardiotoxin-induced skeletal myocyte injury, as assessed by the numbers of regenerating myocytes. 20 visual fields per 
individual mice were observed in the rectus femoris at 14 d after cardiotoxin injection. (i and j) Effects of G-CSF on the handgrip strength (i) and rectus femo-
ris diameter at 14 d (j). (c, e, and h–j) Error bars present mean ± SD (*, P < 0.05). Results in b–e and g–j are from eight independent experiments.JEM VOL. 208, April 11, 2011 
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retrieval using HistoVT One (L6F9587; Nacalai Tesque) and blocking, BrdU 
staining was performed as described in the manufacturer’s protocol.
Myoblast  culturing. C2C12 mouse myoblasts (American Type Culture 
Collection) were cultured in DME/10% FBS (Invitrogen). The medium was 
replaced with DME/2% horse serum (Invitrogen) to induce differentiation. 
Recombinant mouse G-CSF (R&D Systems) was added on the indicated 
days. Inhibition of G-CSF signaling was analyzed by administering an anti–
G-CSFR neutralizing antibody (R&D Systems).
Western blotting. C2C12 cells were treated with G-CSF. Cell extracts were 
prepared at 0, 5, 10, 15, 30, 45, and 60 min after G-CSF stimulation. Protein 
lysates were resolved by SDS-PAGE and transferred to a polyvinylidene 
fluoride  membrane,  followed  by  immunoblotting  with  anti–phospho-
STAT3, anti–phospho-AKT, anti–phospho-ERK, anti–phospho-JNK, and anti–
phospho-p38MAPK  antibodies  (all  from  Cell  Signaling Technology)  and 
horseradish peroxidase–conjugated anti IgG, followed by development with 
the SuperSignal West Pico Chemiluminescent reagent (Thermo Fisher Sci-
entific). The same membrane was retrieved and reblotted with anti-STAT3, 
anti-AKT,  anti-ERK,  anti-JNK,  and  anti-p38MAPK  antibodies  (all  from 
Cell Signaling Technology), respectively.
Luciferase analysis. C2C12 cells plated in DME were transfected with   
Lipofectamine (Invitrogen) according to the manufacturer’s instructions. The 
APRE luciferase plasmid was provided by A. Yoshimura (Keio University, 
Shinjuku, Tokyo, Japan) and used at a dosage of 100 ng. The administered 
dosages of G-CSF were 37.5, 125.0, and 375.0 pg/ml. CMV-Renilla luciferase 
was used as an internal control to normalize for variations in transfection   
efficiency. All of the proteins were expressed at similar levels, as confirmed by 
Western blotting.
Skeletal muscle injury model. 10 µM cardiotoxin (Naja mossambica moss-
ambica; Sigma-Aldrich) diluted in 100 µl PBS was injected into the rectus 
femoris muscles of BL6/J mice using a 27-gauge needle and a 1-ml syringe. 
The needle was inserted deep into the rectus femoris longitudinally to the 
knee. Cardiotoxin was injected along the length of the muscle. The mice in 
the control group were injected with 100 µl PBS. Mice (treated and control 
groups) were sacrificed at various time points after cardiotoxin injection, and 
blood samples (1.0–1.5 ml from each mouse) were collected in heparin-
rinsed syringes.
Handgrip strength testing. 10 µM cardiotoxin (Sigma-Aldrich) diluted in 
100 µl PBS was injected into forearm muscles of BL6/J mice. Five training 
sessions were performed during which the animals were held, facing the bar 
of the grip strength meter (Muromachi Kikai), while the forearm was gently 
restrained by the experimenter. When the unrestrained forepaw is brought 
into contact with the bar of the grip strength meter, the animal grasps the bar, 
after which the animal is gently pulled away from the device. The grip 
strength meter measures the maximal force applied before the animal released 
the bar.
BM transplantation. BM cells were harvested from 8-wk-old enhanced 
GFP (EGFP)–transgenic mice. After irradiation with a single dose of 9.0 Gy, 
the unfractionated EGFP+ BM cells (1 × 106 cells) were injected via the tail 
vein, as described previously (Kawada et al., 2006). To assess chimerism,   
peripheral blood cells were collected from the recipient mice 60 d after BM 
transplantation,  and  the  frequency  of  EGFP+  cells  in  the  population  of   
peripheral nucleated blood cells was determined in a FACS sorter (BD) after 
hemolysis was induced with ammonium chloride to eliminate erythrocytes.
Statistical analysis. The data were analyzed using the StatView J-4.5 soft-
ware (SAS Institute, Inc.). Values are reported as means ± SD. Comparisons 
among groups were performed by one-way analysis of variance. Scheffe’s F 
test was used to determine the level of significance. The probability level   
accepted for significance was P < 0.05.
of G-CSFR is not well understood (Stratos et al., 2007; Naito 
et al., 2009). We proved that BM-derived cells were not di-
rectly involved in skeletal muscle regeneration by G-CSF; 
however, BM-derived cells expressing G-CSF ligand can stim-
ulate skeletal muscle proliferation through myoblast-specific ex-
pression of G-CSFR. This study demonstrates for the first 
time that the factors involved in the inflammatory process 
switch on the process of skeletal muscle regeneration.
Clinically, G-CSF is used to treat patients with neutrope-
nia resulting from immunosuppressive chemotherapy, severe 
congenital neutropenia, life-threatening infections, and stem 
cell harvesting (Hammond et al., 1989; Molineux et al., 1990; 
Welte et al., 1996). Interestingly, myalgia is one of the main 
side effects of G-CSF administration in humans (Taylor et al., 
1989). We may speculate that innate skeletal muscle regener-
ates itself to some extent to adapt the physiological turn over, 
that G-CSF injection stimulates small population of these 
skeletal myoblasts, and that the burst of skeletal myocyte pro-
liferation gives rise to myalgia. The safety and side effects of 
G-CSF have been studied in several clinical settings (Anderlini 
and Champlin, 2008). Therefore, a clinical trial of G-CSF for 
human skeletal muscle injury may be warranted. The results of 
this study underline the importance of G-CSF in skeletal muscle 
development and regeneration and strengthen the case for 
using G-CSF as a skeletal muscle regeneration therapy.
MATERIALS AND METHODS
Whole-mount  in  situ  hybridization. Mouse embryos were removed 
from  wild-type  Institute  of  Cancer  Research  pregnant  mice  on  E10.5. 
Whole-mount in situ hybridization was performed as described previously 
(Yuasa et al., 2005). The full-length cDNAs for mouse c-met, pax3, myoD, and 
mrf4  (available  from  GenBank/EMBL/DDBJ  under  accession  numbers 
NM_008591,  NM_001159520,  NM_010866,  and  NM_008657  [listed  as 
myf6], respectively) were provided by M.E. Buckingham (Pasteur Institute, 
Paris, France). The full-length cDNA for mouse csf3r (GenBank accession 
number NM_007782) was provided by S. Nagata (Osaka University, Suita, 
Osaka, Japan; Fukunaga et al., 1990). The probes were generated using T3 or 
T7 RNA polymerase.
Animals. The myf5 nlacZ mice were a gift from S. Tajbakhsh (Pasteur Institute; 
Tajbakhsh  et  al.,  1996). The  csf3r/  mice  were  a  gift  from  D.C.  Link 
(Washington University School of Medicine, St. Louis, MO; Richards et al., 
2003). All the experimental procedures and protocols were approved by the 
Animal Care and Use Committee of Keio University and conformed to   
the National Institutes of Health Guidelines for the Care and Use of Labora-
tory Animals.
Immunofluorescence. Mouse embryos on E8.5, E9.5, E10.5, and E11.5 
were fixed in 4% paraformaldehyde for 3 h and embedded in Tissue-Tek 
OCT (Sakura) for frozen sectioning. The samples were incubated with Triton 
X-100 for 5 min at room temperature, washed, and incubated with the fol-
lowing primary antibodies: anti–G-CSFR (1:50; Santa Cruz Biotechnology, 
Inc.), anti-Pax3 (1:200; American Type Culture Collection), anti-Pax7 (1:50; 
R&D Systems), anti-MyoD (1:50; Dako), antimyogenin (1:50; Santa Cruz 
Biotechnology, Inc.), antidesmin (Dako), anti–G-CSF (1:50; Santa Cruz Bio-
technology, Inc.), anti–-actinin (1:1,000; Sigma-Aldrich), and anti-GAPDH 
(1:200; Santa Cruz Biotechnology, Inc.). After overnight incubation, bound 
antibodies were visualized with a secondary antibody conjugated to Alexa 
Fluor 488 or 546 (Invitrogen). Nuclei were stained with DAPI (Invitrogen). 
For BrdU staining, a BrdU labeling kit (Roche) was used. After antigen   726 G-CSF promotes skeletal muscle regeneration | Hara et al.
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